Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 1 2Phase 2 1

Status

Completed 4Recruiting 2Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Carcinoma, Non-Small-Cell Lung 173Leukemia, Myeloid, Acute 153Neoplasm Metastasis 146Breast Neoplasms 143Neoplasms 142Colorectal Neoplasms 135Recurrence 104Ovarian Neoplasms 100Pancreatic Neoplasms 81Lung Neoplasms 81Multiple Myeloma 80Advanced Solid Tumor 80Advanced Solid Tumors 74Prostatic Neoplasms 73Stomach Neoplasms 72Squamous Cell Carcinoma of Head and Neck 72Carcinoma, Hepatocellular 67Glioblastoma 65Melanoma 64Lymphoma, Non-Hodgkin 63Triple Negative Breast Neoplasms 57Myelodysplastic Syndromes 54Lymphoma, B-Cell 53Endometrial Neoplasms 53Precursor Cell Lymphoblastic Leukemia-Lymphoma 52Glioma 51Lymphoma 49Brain Neoplasms 46Hematologic Neoplasms 44Carcinoma, Renal Cell 44

Interventions

talimogene laherparepvec 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Recruiting × Neurofibromatoses × Clear all
NCT07102394 2026-05-08

Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1

Johns Hopkins University

Phase 1 Recruiting
10 enrolled
CNS

Neurofibroma, Neurofibromatosis 1, Neurofibromatoses

NCT06961565 2025-12-04

PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas

Pasithea Therapeutics Corp.

Phase 1 Recruiting
56 enrolled
CNS

Neurofibromatosis 1, Neurofibromatoses, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon âš¡